← Back to Search

Millimeter-Wave Holographic Imaging for Solid Tumors

N/A
Waitlist Available
Led By Michael Reilly
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial is studying whether holographic mm-wave imaging can help improve the efficiency and positioning of radiation oncology patients and their overall experience.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Qualitative assessment of holographic image quality
Secondary outcome measures
Image registration agreement between mm-wave holographic images and a cone-beam computed tomography (CBCT)/optical surface image

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (holographic mm-wave imaging)Experimental Treatment1 Intervention
Patients undergo holographic mm-wave imaging in radiotherapy treatment position after initial CT simulation.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,667 Total Patients Enrolled
University of Southern CaliforniaLead Sponsor
905 Previous Clinical Trials
1,596,278 Total Patients Enrolled
Michael ReillyPrincipal InvestigatorUniversity of Southern California

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research require additional participants?

"As indicated on clinicaltrials.gov, this medical study is not presently recruiting patients. The trial was initially uploaded to the website on December 1st 2022 and last amended August 5th of that same year. Fortunately 9 other trials are currently admitting participants at this time."

Answered by AI
~0 spots leftby Apr 2025